Rob Baker
Chief Executive Officer at CAMBRIDGE COGNITION HOLDINGS PLC
Replay available
Results for the year ended 31 December 2025 Q&A Session hosted by Cambridge Cognition Holdings (LSE:COG) on Investor Meet Company, held 2026-04-13.

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:01 Good afternoon, ladies and gentlemen, and welcome to the CAMBRIDGE COGNITION HOLDINGS PLC Q and A session. Questions are encouraged. They can be submitted at any time via the q and a tab that's just situated on the right hand corner of your screen. Please just simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today, and we'll publish our responses where it's appropriate to do so on the Investor Meet company platform. Before we begin, we would just like to submit the following poll. And if you'd give that your kind attention, I'm sure the company would be most grateful. And I would now like to hand you over to CEO, Rob Baker. Rob, good afternoon, sir. Good afternoon, and thank you all for joining us today for a q and a session on the 2025 results for Cambridge Cognition. As I say, I'm Rob Baker, CEO of Cambridge Cognition. I'm joined by I'm Ronald Oberbenshire.
0:50 I'm chief financial officer. And before we jump into the q and a sessions, I just want to take an opportunity to just recap some of the highlights of those 2025 results. Hopefully, you've had a chance to review the presentation that's prerecorded previously, an opportunity to read the reports, look forward to your questions during this thirty minute session today. So in 2025, we really set back that return to growth and expanding market opportunities. The sales orders returned to growth up to 12,800,000, up 73% year on year. The order book up 25% from the prior year position at 6.5 mid 16,500,000. Whilst the revenue of 9.4 is down 10%, again, reflects the weaker opening order book and prior sales challenges during '23 and '24.
1:40 But as we sit here today, we sat with a line of sight of 9,500,000 of underpinned order book for 2026, really making sure we can step on in terms of that return to growth. We've seen that commercial and operational progress return in terms of strengthening of the Tier one focus and the delivery to continuous operational excellence, the strategic process and progress made in CANTAB pathway and addressing the additional opportunities within health care and consumer. And as we positively look for the output, we're seeing that active and growing, CNS market, the minimum coverage of those, revenues for 2026, a strong order book, and a growing pipeline of opportunities. We're pleased to be able to take this opportunity to share any of the questions. I'll take the opportunity to read them out and farm them between us. And I'll start with, could you provide a little bit more detail on the Apple and Biogen collaboration?
2:35 This was a great collaboration that was set out a number of years ago. And in twenty twenty five q one, the results were published by Apple and Biogen in terms of the study around that project intuition. This was a cohort of 23,000 participants active within a study that we're supporting with with our technology, both our traditional CANTAB assessments and also high frequency assessments that were also used. This was critical to being able to demonstrate our real world application of our tools and also within a remote setting, but also the data that was able to be agreed and licensed to be able to share and support the development of additional data products that were coming from that 23 participant 23,000 participant cohort.
3:21 And we're now using that to actually build that in as part of our health care and consumer application. It allows us to develop a strong normative dataset that is essentially a set of data of health participants which show the progress of the disease over time, and that supports us in terms of when we're doing cross sectional testing within that. And so we're pleased by that progress made, and I think there's a lot of more work to be done to build on that progress. It also sets that apart. It's a piece of data and a dataset that is challenging to collect. It's a large study that was obviously administered, and now being able to use that to support our further data, sort of ambitions and our data acquisition strategy is absolutely critical. So something that we're pleased to have been part of, demonstrated our tools, the real world application, and now supports us as we invest into that next stage of our data tools and available for all the different markets we are looking to address.
4:15 Another question that's been presubmitted is following the change in nominated adviser and joint broker to Panio Liberum. What are the primary adopters for your institutional outreach in 2026? Yeah. I took that one. Like mine. So you will have seen that over the course of the last, really eighteen months since the management change, one of our key objectives is to be transparent and to be present with investors. So the company started using and I'd like to thank our friends at Investment Company for having us. This is the this is one of several that we've done over the course of the last year or so to engage not just with our institutional investors, but also with our private investors to make things available. This time around, we decided that we would prerecord today's presentation and that that presentation was available at 07:00 this morning. So, actually, all investors could see the same presentation that we're using with institutional investors this week at the start of this week. Yep. We took the decision to change our nominated adviser and joint broker.
5:25 The team from Dowgate moved to Singer. We have retained Singer for the long term, and we took the decision that after a number of years with Panmure, we thanked them for their time and service, that it was time for a refresh, and we moved the nomad and joint broker to Cavendish. It's a group of people who've been courting us for a significant period of time. They've got a great client roster, and that really helps us. And the decision was also driven by our realization that Cambridge Cognition has for too long been considered a health care company, a medical device company, and even worse, a biotech company. The reality is we are a health tech company. We're based upon high-tech software deliverables around the neurosciences space, and so we have and coverage will commence by both analysts, I hope, this week with Mike Mitchell at CAMBRIDGE, who's a a highly ranked health care analyst, and with Harry Evans here at Singer, whose offices were in this afternoon, who is a tech analyst and highly respected tech analyst at that. So we got both angles covered. We think that that's important for giving all investors that true read on where the company is. We have done more investor meetings this year already than we probably did for the whole of last year, and our commitment to be present, to take questions, and be transparent is is at the forefront.
6:57 Thanks, Rob. So next up is, you talk about investment in science and technology platforms. Given AI and your valuable data, could you give us a rough idea of the magnitude of the spend you're expecting? Will it be a company, accommodated in a, 2,000,000 annual r and d spend, or will there be a bigger hike? And what will be the business gain from this investment? I think investing into our technical stack and our science is absolutely critical to ensure that we remain at the forefront of of our field and continue to drive the field forward importantly as well. We are have invested over thirty to forty years of building tools that are being tested, have been validated in clinical trials through academic studies, over 3,600 peer reviewed publications that have been published using our tools.
7:47 And so for us to keep driving the satellite opportunities around what we've already developed and built in over that 43, set of both touchscreen and voice based assessments, we see an opportunity to keep driving into that space in terms of other areas, to be able to either utilize the existing IP that we have, and that's a really good example of what we did with CANTAB pathway. We took our existing technical platform. We took our existing set of assessments and packaged it up in a way that that wrapped it around, that allowed us to vend it very easily to partners through, an API call or software, some integration as such, that allowed us to leverage what we'd already invested into. And we believe there's opportunities to do the same thing with some of our existing platform as well, whether that be the likes of our voice platform to continue to drive the path of automatic speech recognition, to maintain those quality measures that our customers know us for, respect us, and trust us for, to be able to bring some of the optimization of scale by using more automatic speech recognition within that pipeline.
8:54 So the real term return on investment of these these investments that we identify really allow us to kind of push in and and see near term revenue uptick or margin increase by actually greater efficiencies from that perspective. So in terms of what that will be incumbent to, we do expect to to continue to invest more into that space. And I think the current r and d piece also includes maintenance as well and investing into our technical stack as well to keep that up. And I wonder whether you wanna expand a little on that. Yeah. I do. And and there's another question coming, which I'm going to read because I think it's relevant to this whole theme, which is a question that says you reported last year you had to reduce your r and d spend because of financial constraints. You report today that you're reviewing your investment in science and tech. Are financial constraints affecting your ability to do cutting edge research and product development?
9:47 And I think this this plays neatly into that. The the shortest answer to that investor's question is no. Mhmm. The longer answer is we are a tech company. We are a science company, and we need to invest. They push towards reducing the cost base, rightsizing the cost base is at the heart of what we're doing. The push towards generating profit from our business areas, and you'll see the enhanced segmental reporting that we're giving you, which clearly shows you the profit that we're delivering. The the thesis here is to look at where in the business should we be to be investing across the business so that we are relevant not just today and next year, but for the years to come. The move into health care with CAMBRIDGE pathway was a really clever move, I think, from our scientists who instead of saying, let's have new tasks that are fit for the health care market or the consumer market, it was to say, let's repurpose some of the 43 tasks that we already have to be able to invest in that space.
10:56 So will we continue to be at the cutting edge? Yes. Yeah. Are we going to massively increase investment to go back to a period of raising money, recording losses? The answer is no. The objective is to see this business at or ahead of breakeven after investment so that we really can invest for the future and see that growth in revenue. As we're looking at investment opportunities, we ask ourselves the following question. How much is it going to take, and how long is it going to take? When we have it, what is the return, the output that we want? Is it increased revenue? Is it reduced costs, or is it both? And then we ask the question, and this is really hard in this company. The scientists are sort of like, we just wanna do stuff. And we say, well, what's your go to market strategy, and what's your return on investment? Because we can't move forward with that investment if we don't have a clear method of measuring why is it relevant. Yeah. But I think the the caps of the '25 build on this the the work we did in '24 was it made us sharper, more astute to those areas and recognize how we do more with what we've already got so that when we do invest, we can really make sure it is a growth driver versus just holding steady. Correct.
12:13 So just going back through. Thank you for those questions. We've got another piece of edit. How do you see the cash for cash runway working out? Okay. Sounds like it's been kind of a question to me. So I think here, what we've got to do is we've to say we brought the company to a point where we are EBITDA, slight loss this year, EBITDA positive last year. We got to the point where we were of cash flow from operations net positive for the year. I think it's important for investors to recognize that the debt facility that was taken out in 2023 will be fully repaid this August, so there'll be no drain on cash from that facility. The fundraising that we did last year that was designed to put working capital into the business was very effective due to the nature of clinical studies.
13:07 The flow of cash from them depends upon hitting milestones, and therefore having that buffer within the business is critically important. And I think the question, how do you see the cash runway, is based around that thesis that somehow we're an investment stage only company, and I think that's the thesis that's changed. We're taking this business to an EBITDA, neutral to an EBITDA positive area. We want our individual business pillars to be profitable and cash generative, and then investment will then layer on as cash funds permit and to make sure that we're not at that point where, oh, dear, all of a sudden, the company is running out of money.
13:53 I think that's a that's a major change in thesis for the organization as a whole. There you go. Thank you. So next one is is the pilot study with the health technology company new? So the answer short answer is yes. The update that we provided in the release and in the accounts today referenced a new IRB approved, pilot study that we are running with a health technology company, at this point. For us, it's always been as we've set out during May last year when we came and spoke to you and provided an update of where we're at that we believe there was an opportunity to grow our technology and our application into the health care, premium health care, and in the consumer side. We obviously provided the update in January around the pilot in the the premium health care space with the Pan European company.
14:45 We then were looking at how we build out from that perspective, and the announcement that's included in today's update is around that move and supporting that consumer space as well. Generally speaking, we have a vision about how we bring, you know, for me personally, how we bring COGNITION to be as easily and readily measurable as the steps on your watch. And this is one of the steps that comes alongside that. And the key bit is recognizing the opportunity to combine both the physiological data alongside the likes of cognitive data and cognitive health and providing that n equals one scenario where people can actually understand and measure their health. So at this time, yeah, we're in a business we are are not able to name that that partner, but at the point by it is an update for this study and puts now both the pilot and sentinels in place for the health care, for the consumer space, and starting to deliver on those promises of unlocking the full potential of the technology stack of the science that this business has been building over the last thirty to forty years and also recognizing how it creates, the flywheel of connection between our academic customers, our clinical trial space, our, health care customers, and then subsequently consumer, how we see that sort of data ecosystem evolving over time. So we're excited about that step, but, yeah, that time is my update.
16:08 The next one, have you seen or do you expect any headwinds from the Trump administration or recent geopolitical issues? I think we always remain obviously observed. I think there are potentials we have seen, certainly a number of or cautious concerns or delays around some of the the contracting, for example, for country selection, which could be related down to those issues from that perspective. But at the same point, we have really strong relationships. And one of those steps into focusing around the tier one customer base, that step we made at the back end of twenty twenty four and cemented through '25 and further instilled with additional sales headcount during December 2025 was to ensure that we could really deliver that move into that tier one because of the stability that provides, the line of sight it provides, but also the opportunity to really ensure we're working across multiple disease areas within those pipelines as well, and we're we're seeing that come to fruition.
17:07 So I think there are challenges to be addressed, but I also think we're well positioned. We've got a well experienced management team and a leadership team and an operational team that is negating that. We saw that through last year when it came to likes of tariffs, and we were able to address anything that may arise when it came to any of our hardware shipments in and out. It was proactively, and the relationship with our customers as well is very clear, transparent from that perspective, which which supports us navigating any of those that that come through. Anything to add or you feel I just wish we were in a period of greater political stability, both internationally and within The United States. So let's move on to the next one. I thought your going concern statement was very thorough.
17:54 I read the reverse stress test. You mentioned a consistent reduction in sales orders, meaning a nil cash balance. Can you give oh, sorry. Just moved up. Yeah. Can you give us guidance on how much the reduction would need to be? Okay. So thank you very much for having read it carefully. I think you would say that the whole of the report accounts, we have increased the level of disclosure across the business as a whole. We're trying to be as transparent as we can. You would also see that we have new auditors on board. I think they've done an extremely thorough job. I think we've had a more thorough audit this year. And, actually, if you were to compare the audit phase, we've saved 50,000 as well. So really good. And that goes to the heart of the disclosure that's being put in there.
18:47 We've received some really clear guidance and and help from them both in their own disclosure, in their report, and also in the concern statement. I'm going to give some response, but I'm not going to give you a full response in terms of how much does it need to be because what they're looking at is our internal sales forecasts. And the reverse stress case is based on that. We do not publish our internal sales forecasts. The analysts have theirs. We have ours. We try and make sure that there is headroom in between those. But what I will do is to try and give you some degree of comfort around this. Going concern is one of those matters that we take very seriously. We have to generate enough selling in order to be able to make that work. We've published the q one sales number.
19:39 It wasn't as large as we wanted, but that's because we had sales which has slipped over into the opening weeks of April, I can confirm that we have sent a very significant number of contracts out to customers, up to the first ten calendar days being Friday of last week of April. The pipeline that we have of new business which we are chasing is more than adequate to make sure that the going concern challenge is easily met. If we perform well, then the going concern issue is not even relevant.
20:26 However, in the spirit of full disclosure, the auditors took a downside look. We took a downside look. And I think the responsible thing for a company with only a million pounds on its balance sheet in markets, which can be sometimes volatile, is to be very clear about it. And the auditors came in very early on and said, we think the appropriate thing to do is to note this is a material uncertainty. And we said, we agree with you. So I I hope that gives you an adequate answer to that question. Is it something we are worried about? No. Is it something we pay real attention to, every single working week? The answer is yes. So it's not an issue that would suddenly creep up on us. We have plenty of forward cash planning, pieces in place. And as I say, the new selling that we're doing, we're highly encouraged by, the sales that we've made in April, which is beyond the first quarter, and we believe that q two will be strong to really propel us to growth.
21:28 Thank you. This kind of maybe builds on a little bit from that, but what are the 2026 consensus forecasts, and how confident are you that you will meet them? So I think this is one where we have as a result of the changes in both of our joint brokers, we're expecting both analysts to be publishing in the next few days, certainly within a week of now, and we'll get those forecasts out there. And I think where both analysts are coming from is that we may see them come back with slightly reduced forecasts, but that is in large part because we are in large part because we are they want to make sure that when we hit our numbers, we hit their numbers, and hopefully, they can move them up. I think one of the challenges that were faced over '23 and '22 is that the company was not performing.
22:26 The analysts were putting numbers into the market. The company wasn't meeting them, and we were constantly chasing our tail downwards. I think the investment thesis will be easily met based upon their forecast. So I'm afraid that that there are no current analysts in the market, but hopefully within a week, you'll end up with two new initiations and to reset them. You've explained that some of the big contracts you hope to win in q one have seen extended negotiations. Could you provide some more information on what's causing the delays? Are you being put through further competitive rounds? Are customers waiting for The Middle East to settle down? Really great question. I think builds on some of that area that we picked out with the the question of some of the geopolitical challenges that sit across. I think the nature of the space that we're working in in terms of that large pharma organization, you know, we've got good deep relationships from that perspective, and those contracting processes generally are quite sick as you build them build them through and start to progress them.
23:24 So it's just the nature of some of it of just the pure timing of when we move from our proposals into our sort of awarded and then contracting phases. It's not the case we're putting being put through further competitive rounds from that perspective, certainly that we're aware of. It's more the case of a round ensuring, for example, and one of them is they're refining their country selection within their protocols. So they're looking at how they're applying it. That could be related to some of the geopolitical tensions, but that's nonconfirmed from from their side. But it's nature of building strong deep relationships that we've got that open dialogue, that open communication with them in terms of where they're into, and just the nature of these these longer term later phase contracts will take a little bit more time to go through and and contract.
24:10 But we are encouraged by the the growth of the overall order book in terms of underpinning that forecast when we think about the challenges that might erode with different contracts moving in and out. It's about ensuring you've got the right balance and volume of of multiple deals that you're working on at the same time. So I think that speaks to the progress made within the, commercial teams, the teams that we've introduced. So I go back to reflecting that we had four new sales representatives that joined us in in late December. They've come in and and successfully already got their feet under the table and delivering in that area. And as they push and support us going through to get those deals closed as well. So I think as we as we look forward, it's continuing to make sure we have good, deep relationships with our customers, and we have the effective contracting process as well. Yeah. I think to answer the last part of the question, are we waiting for The Middle East to settle down? We haven't seen a direct impact of The Middle East at this point in time. But, clearly, it's a it's a it's an insane situation, and everybody will be better when that situation calms down. And I'll refer back to the answer I gave, which is we have, in the first ten calendar days of April, sent out some material contracts for signature. So some of the stuff that had slipped, has already been sent for execution, and, hopefully, Monday, Tuesday, Wednesday of this week, we'll get some contracts back on that. So we'll be pleased about that, but that just that falls into the the normal mix. So so I think there's probably time for one last question.
25:40 On what does the first patient dosing for Monument Therapeutics MT1988 mean for Cambridge Commission's equity value and technical validation? Obviously, the milestone of Monument hitting that first dosing, I think we are we, you know, celebrate our partners in that in terms of the work that they've done, and certainly that Jenny Barn and the team over there at Monument have done a great job to hit that milestone. I think as we look at that, obviously, the progress of the phase two study will be will be key to see that, but we don't expect to see much readout of that in terms of the in the shorter term. But, obviously, more in the medium term, it relates to what that net present value would be in terms of the whole value of of those of that work being done. And the technical validation sits behind that is ensuring, obviously, how our tools are also being applied within that area as well. I don't know whether you've got any further thoughts. I was gonna I was gonna say the following really from a a much more of technical accounting background is that the monument valuation is pegged to the valuation at the last financing round.
26:42 That's the 1.8 that we recorded on the balance sheet. At least in, corporate finance risk adjusted net present value theory, the dosing of the first patient is a really positive step forwards. It brings forward the date on which the data from that phase two study will be available. It positively and definitively kicks off that study and, at one level, reduces the risk and therefore increases the theoretical net present value. But this is an area that the auditors spent significant time with us on challenging, I think, robustly and appropriately the use of the valuation metric. And, actually, when we came around to it, we thought that the disclosure in the report accounts was appropriate.
27:32 And so what we've said is, clearly, the results of, that study will have a very significant either positive or negative valuation move. It's impossible today to be able to say where that lies, And therefore, we thought that the appropriate thing to do was to continue that value at 1,800,000 on the balance sheet and to give the reader really high quality disclosure so that they can assess what risks around that 1.8 are. It's not a risk free investment by any stretch of the imagination, but it's good. Okay. Brilliant. Thank you. That brings us to the end of the thirty minutes. If there are any questions that we haven't been able to answer, I know through this platform, we'll be an opportunity to provide those back, and so we're endeavored to do so. So it's with me just to say a big thank you for taking the time today, and the opportunity and time to be able to answer these questions, and hopefully, you've had the chance to obviously read and view the presentation that we've done before. We have returned to growth. We see a positive outlook in terms of the opportunities within those expanded markets.
28:40 Our focus will clearly be to deliver that revenue growth, to ensure that we continue the commercial momentum, to maximize the opportunities of these pilots that we're progressing in and also supporting that growth by wisely and selectively investing into areas that really help accelerate that flywheel of growth. We look forward to providing you updates through the course of 2026, and thank you very much. Thank you. Perfect, guys. That's great. And thank you very much indeed for updating investors, this afternoon. Could I please ask investors not to close this session as you will now be automatically redirected to provide your feedback in order that the management team can really better understand your views and expectations? This will only take a few moments to complete, but I'm sure it'll be greatly valued by the company. On behalf of management team of Cambridge Cognition Holdings PLC, we would like to thank you for attending today's presentation.
29:29 That now concludes today's session. So good afternoon to you all.
Follow Cambridge Cognition Holdings PLC into a list and get an email when it puts out news.
Chief Executive Officer at CAMBRIDGE COGNITION HOLDINGS PLC
Chief Financial Officer and Head of Corporate Development at CAMBRIDGE COGNITION HOLDINGS PLC